Metabolon, Inc.

Duke University

Syngenta Participations Ag

Massachusetts General Hospital Corporation

University of Michigan

Matthew W Mitchell

Arul M Chinnaiyan

Kay A Lawton

Michael V Milburn

Danny Alexander

Walter Gall

Yun Fu Hu

Costel Chirila

Jacob Wulff

Adam D Kennedy

John A Ryals

Lining Guo

Anne M Evans

Meredith V Brown

Nalini M Desai

Rima Kaddurah-Daouk

Alvin Berger

K Ranga R Krishnan

Jonathan Cohn

Arun Sreekumar

Lisa A Paige

Don Harvan

Shaun Lonergan

Christopher William Beecher

Robert Brown

Merit Cudkowicz

Christopher Beecher

Kateri Duncan

Andrea Eckhart

David Carl Steffens

Thomas J Jönsson

Mike Milburn

Ryan Douglas Michalek

Bryan Wittmann

Chris Beecher

A method of assessing the quality of a biological sample while maintaining the viability of the biological sample for intended use analysis is described herein. The method includes analyzing a biological sample obtained from a subject for an intended use, assessing the quality of the biological sample using one or more biomarkers of sample quality, and simultaneously performing intended use analysis on the same sample. Assessing the quality of the sample can include assessing compliance with sample handling protocols and assessing subject compliance.

Automated sample quality assessment

Methods are described herein for small molecule biochemical profiling of an individual subject for diagnosis of a disease or disorder, facilitating diagnosis of a disease or disorder, and/or identifying an increased risk of developing a disease or disorder in the individual subject. Aberrant levels of small molecules present in a sample from an individual subject are identified and diagnostic information relevant to the individual subject is obtained based on the identified aberrant levels. The obtained diagnostic information includes one or more of an identification of at least one biochemical pathway associated with the identified subset of the small molecules having aberrant levels, an identification at least one disease or disorder associated with the identified subset of the small molecules having aberrant levels, and an identification of at least one recommended follow up test associated with the identified subset of the small molecules having aberrant levels.

Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment

Biomarkers relating to cardiovascular disease, including atherosclerosis and cardiomyopathy, are provided, as well as methods for using such biomarkers as biomarkers for cardiovascular disease. In addition, methods for modulating the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for cardiovascular disease, including atherosclerosis and cardiomyopathy.

Biomarkers for cardiovascular diseases and methods using the same

The present invention relates to the fields of agriculture, plant breeding or genetic engineering for plants with increased yield, crop forecasting and crop management. In particular, the methods herein describe novel methods of predicting a plant's yield through the measurement of specific metabolites either individually or in combination with one another in a specific plant reproductive tissue. The plant predictive methods described herein may be used to predict yield of plant populations as well as allow for more efficient crop management practices (e.g. amount and timing of chemical applications or amount of irrigation water applied to a field).

Methods of predicting crop yield using metabolic profiling

Biomarkers relating to insulin resistance are provided, as well as methods for using the same as biomarkers for insulin resistance. Also provided are suites of small molecule entities as biomarkers for insulin resistance.

Biomarkers for insulin resistance and methods using the same

The present invention provides various biomarkers of amyotrophic lateral sclerosis (ALS). The present invention also provides various methods of using the biomarkers, including methods for diagnosis of ALS, methods of determining predisposition to ALS, methods of monitoring progression/regression of ALS, methods of assessing efficacy of compositions for treating ALS, methods of screening compositions for activity in modulating biomarkers of ALS, methods of treating ALS, as well as other methods based on biomarkers of ALS.

Biomarkers for amyotrophic lateral sclerosis and methods using the same

Biomarkers relating to insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy are provided, as well as methods for using such biomarkers as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy. In addition, methods for modulating the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy.

Biomarkers for impaired glucose tolerance and methods using the same

Biomarkers relating to insulin resistance are provided, as well as methods for using such biomarkers as biomarkers for insulin resistance. These biomarkers may be used to monitor the progression or regression of insulin resistance or to monitor the efficacy of insulin resistance treatment. Also provided are suites of small molecule entities as biomarkers for insulin resistance.

Biomarkers for monitoring insulin resistance and methods using the same

Methods for identifying and evaluating suites of biochemical and/or gene entities useful as biomarkers for early prediction of prostate cancer, disease grading, target identification/validation, and monitoring of drug efficacy are provided. Also provided are suites of small molecule entities as biomarkers for prostate cancer.

Biomarkers for prostate cancer and methods using the same

The present invention provides various biomarkers of depression. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of depression, methods of determining predisposition to depression, methods of monitoring progression/regression of depression, methods of assessing efficacy of compositions for treating depression, methods of screening compositions for activity in modulating biomarkers of depression, methods of treating depression, as well as other methods based on biomarkers of depression.

Biomarkers for depression and methods using the same

Method for determining insulin sensitivity with biomarkers

Biomarkers relating to metabolic age are provided, as well as methods for using such biomarkers as biomarkers for determining metabolic age. In addition, methods for modulating the metabolic age of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for metabolic age.

Biomarkers related to metabolic age and methods using the same

Growing community of inventors

Durham, NC, United States of America

Matthew W Mitchell